On March 31, 2023 at 14:41:46 ET an unusually large
$80.49K block of Call contracts in Phathom Pharmaceuticals
(PHAT) was bought,
with a strike price of $7.50 / share, expiring in 49 days (on May 19, 2023).
Fintel tracks all large options trades, and the premium spent on this trade was � sigmas above the mean, placing it in the percentile of all recent large trades made in PHAT options.
This trade was first picked up on Fintel’s real time Unusual Option Trades
tool, where unusual option trades are highlighted.
Analyst Price Forecast Suggests 165.00% Upside
As of March 30, 2023,
the average one-year price target for Phathom Pharmaceuticals is $18.02.
The forecasts range from a low of $9.09 to a high of $25.20.
The average price target represents an increase of 165.00% from its latest reported closing price of $6.80.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Phathom Pharmaceuticals
is $37MM.
The projected annual non-GAAP EPS
is -$5.64.
What is the Fund Sentiment?
There are 221 funds or institutions reporting positions in Phathom Pharmaceuticals.
This is a decrease
of
9
owner(s) or 3.91% in the last quarter.
Average portfolio weight of all funds dedicated to PHAT is 0.13%,
a decrease
of 15.70%.
Total shares owned by institutions decreased
in the last three months by 7.49% to 31,352K shares.
The put/call ratio of PHAT is 0.06, indicating a
bullish
outlook.
What are Large Shareholders Doing?
Frazier Life Sciences Management
holds 8,407K shares
representing 20.15% ownership of the company.
No change in the last quarter.
Medicxi Ventures Management
holds 2,484K shares
representing 5.95% ownership of the company.
No change in the last quarter.
Invesco
holds 2,208K shares
representing 5.29% ownership of the company.
In it’s prior filing, the firm reported owning 2,068K shares, representing
an increase
of 6.33%.
The firm
decreased
its portfolio allocation in PHAT by 1.62% over the last quarter.
Avidity Partners Management
holds 1,900K shares
representing 4.55% ownership of the company.
In it’s prior filing, the firm reported owning 1,907K shares, representing
a decrease
of 0.36%.
The firm
increased
its portfolio allocation in PHAT by 7.52% over the last quarter.
Ensign Peak Advisors
holds 1,761K shares
representing 4.22% ownership of the company.
No change in the last quarter.
Phathom Pharmaceuticals Background Information
(This description is provided by the company.)
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. Phathom has in-licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, a novel potassium competitive acid blocker (P-CAB) in late-stage development for the treatment of acid-related disorders.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
